VKTX Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own VKTX shares is 549, representing 74.7% of the company's common stock.

RHENMAN & PARTNERS ASSET MANAGEMENT AB, in the last quarter, reduced its stake in VKTX by -19.44% restricting it's holding to 145 thousand shares of worth nearly $11.89M. RAFFERTY ASSET MANAGEMENT, LLC also lessened -69.09% of the VKTX shares from its portfolio, reducing its holding to 127.76 thousand shares of worth $10.48M. BALYASNY ASSET MANAGEMENT L.P. also shunned VKTX shares holding by -95.16% last quarter which brought its holding to 108.6 thousand shares worth $8.90M.

As per its latest 13F filing, AVORO CAPITAL ADVISORS LLC increased its stake in VKTX by 100% in the last quarter. The institutional holder raised its holding to 3.59 million shares having worth more than $294.38M. CI INVESTMENTS INC. also added 100% more shares of VKTX to its portfolio, raising its holding to 171.13 thousand shares of worth $14.03M. SWISS NATIONAL BANK also increased its VKTX shares holding by 0.6% which brought its holding to 168.6 thousand shares worth $13.83M.

The insider with the most stakes in VKTX is LIGAND PHARMACEUTICALS INC , 10 percent owner at the company. Additionally, VKTX stock is highly held by President & CEO Lian Brian and Chief Operating Officer Mancini Marianna among others.

Company executives, directors, and other insiders own 2.72% percent of Viking Therapeutics, Inc.'s stock. Within the last six months, there have been 9 transaction(s) in which VKTX insiders have sold stock, totaling 69.51K shares. Insiders that have sold shares include MANCINI MARIANNA, LIAN BRIAN, and ZANTE GREG.

There have been 0 transaction(s) during the past 6-months in which Viking Therapeutics, Inc. insiders have bought stock, totalling 0 shares

Around 5.43M Viking Therapeutics, Inc. shares are held by insiders, which represents about 2.72% of VKTX stock.

VKTX 10 percent owner, LIGAND PHARMACEUTICALS INC holds the largest portfolio of the company's shares. VKTX shares owned by LIGAND total nearly 5.82 million.

AVORO CAPITAL ADVISORS LLC is the largest institutional owner in VKTX which holds 3.59 million shares worth $294.38M or 3.81% of the total VKTX shares outstanding followed by CI INVESTMENTS INC. with ownership of 171.13 thousand shares representing 0.18% of the VKTX ownership. SWISS NATIONAL BANK is the third largest stakeholder with 168.6 thousand shares or 0.18% of the ownership worth more than $13.83M.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the VKTX is concerned, it is a stock which is optionable.

Number of VKTX shares short is 23.93M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 111.57M shares of VKTX are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, VKTX has 109.09M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for VKTX is 6.84.